Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000058946 | SCV000110797 | likely pathogenic | not provided | 2015-05-19 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000150058 | SCV001205880 | pathogenic | Metachromatic leukodystrophy | 2023-12-05 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 392 of the ARSA protein (p.Arg392Gln). This variant is present in population databases (rs199476391, gnomAD 0.01%). This missense change has been observed in individual(s) with metachromatic leukodystrophy (PMID: 9452102, 20339381, 26462614; Invitae). This variant is also known as Arg390Gln. ClinVar contains an entry for this variant (Variation ID: 68116). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ARSA protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects ARSA function (PMID: 9452102). For these reasons, this variant has been classified as Pathogenic. |
Uni |
RCV000058946 | SCV000090467 | not provided | not provided | no assertion provided | not provided | ||
Counsyl | RCV000150058 | SCV000800617 | uncertain significance | Metachromatic leukodystrophy | 2017-11-07 | flagged submission | clinical testing | |
Natera, |
RCV000150058 | SCV002081641 | pathogenic | Metachromatic leukodystrophy | 2020-07-27 | no assertion criteria provided | clinical testing | |
Gelb Laboratory, |
RCV000150058 | SCV005046774 | not provided | Metachromatic leukodystrophy | no assertion provided | in vitro |